Tosk has had excellent though preliminary results of its recently inaugurated human trials for its TK-90 drug, which protects against mucositis.
December 1, 2017
Tosk has been awarded a $2 million grant from National Cancer Institute to continue the company’s TK-kRAS research program.
February 6, 2018

Preclinical efficiency testing in a rat model of doxorubicin-induced cardiotoxicity reduction has demonstrated statistically significant protection.

TK-39, Tosk’s second patented product, which blocks damage to the heart (cardiotoxicity) resulting from widely used cancer drugs known as anthracyclines, has proved preclinical efficacy testing in a rat model.

Tosk’s R&D team demonstrated that TK-39 provided statistically significant protection in rats with doxorubicin-induced cardiotoxcitity, and the experiment has been successfully replicated. The model examines the pumping capacity of the heart following treatment with doxorubicin. Survival also was substantially better in the mammals dosed with TK-39.